| Market Capitalization (Millions $) |
- |
| Shares
Outstanding (Millions) |
235 |
| Employees |
2,931 |
| Revenues (TTM) (Millions $) |
2,012 |
| Net Income (TTM) (Millions $) |
-2,450 |
| Cash Flow (TTM) (Millions $) |
-219 |
| Capital Exp. (TTM) (Millions $) |
94 |
Business Description
Endo International Plc is a publicly-traded pharmaceutical company that specializes in manufacturing and marketing pharmaceuticals and medical devices. The company headquarters is located in Dublin, Ireland, with additional offices and facilities in the United States, Canada, and Europe. Endo International Plc operates multiple subsidiaries, including Endo Pharmaceuticals, Par Pharmaceutical Companies, Qualitest Pharmaceuticals, and AMS (Amerigen Medical Specialties).
Endo International Plc's history can be traced back to the 1920s when it was established as The Endocrine Company. Over the next several decades, the company grew and diversified its product offerings. In 1997, it became known as Endo Pharmaceuticals Holdings Inc. and went public in 2000. Since then, Endo International Plc has undergone several strategic acquisitions and divestitures to focus on key therapeutic areas, including pain management, urology, and oncology.
Endo International Plc's product portfolio includes both branded and generic pharmaceuticals. Its branded products cater to various medical needs, including chronic pain, urological disorders, and endometriosis. Among its leading branded products are Lidoderm, Opana ER, Supprelin LA, and Vantas. In addition to branded pharmaceuticals, Endo International Plc also sells a range of generic medications under the Par label.
Aside from pharmaceuticals, Endo International Plc also offers medical devices through its AMS subsidiary. The company's leading medical device is the MiniArc Precise Single-Incision Sling System, which helps treat stress urinary incontinence in women.
In recent years, Endo International Plc has faced several challenges, including high debt and legal settlements. The company has taken steps to address these issues, including divesting non-core assets and restructuring its business operations.
Overall, Endo International Plc is a well-established pharmaceutical company that offers a diverse range of branded and generic drugs as well as medical devices. Despite facing challenges, the company has continued to invest in research and development and expand its product offerings, making it a significant player in the global pharmaceutical industry.
Company Address: First Floor, Minerva House, Simmonscourt Road Ballsbridge, Dublin 4, 0
Company Phone Number: 1-268-2000 Stock Exchange / Ticker: ENDPQ
|
%
0.72%